Positive and negative regulation of endogenous genes by designed transcription factors.

Gene regulation by imposed localization was studied by using designed zinc finger proteins that bind 18-bp DNA sequences in the 5' untranslated regions of the protooncogenes erbB-2 and erbB-3. Transcription factors were generated by fusion of the DNA-binding proteins to repression or activation domains. When introduced into cells these transcription factors acted as dominant repressors or activators of, respectively, endogenous erbB-2 or erbB-3 gene expression. Significantly, imposed regulation of the two genes was highly specific, despite the fact that the transcription factor binding sites targeted in erbB-2 and erbB-3 share 15 of 18 nucleotides. Regulation of erbB-2 gene expression was observed in cells derived from several species that conserve the DNA target sequence. Repression of erbB-2 in SKBR3 breast cancer cells inhibited cell-cycle progression by inducing a G(1) accumulation, suggesting the potential of designed transcription factors for cancer gene therapy. These results demonstrate the willful up- and down-regulation of endogenous genes, and provide an additional means to alter biological systems.

[1]  M. Shales,et al.  Reduced binding of TFIID to transcriptionally compromised mutants of VP16 , 1991, Nature.

[2]  D J Segal,et al.  Toward controlling gene expression at will: selection and design of zinc finger domains recognizing each of the 5'-GNN-3' DNA target sequences. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Hung,et al.  Cloning and characterization of the mouse neu promoter. , 1992, Oncogene.

[4]  D J Segal,et al.  Design of polydactyl zinc-finger proteins for unique addressing within complex genomes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Wagner,et al.  In pursuit of antisense. , 1996, Nature.

[6]  F. Holstege,et al.  Transcriptional regulation: contending with complexity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Kraus,et al.  Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D. Curiel,et al.  Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. , 1994, Gene therapy.

[9]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[10]  A Klug,et al.  Toward a code for the interactions of zinc fingers with DNA: selection of randomized fingers displayed on phage. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Gossen,et al.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[12]  N. Hynes,et al.  Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. , 1992, The Journal of biological chemistry.

[13]  G. Plowman,et al.  Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Peter B. Dervan,et al.  Regulation of gene expression by small molecules , 1997, Nature.

[15]  M. Ptashne,et al.  Imposing specificity by localization: mechanism and evolvability , 1998, Current Biology.

[16]  N. Hynes,et al.  Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling , 1995, Molecular and cellular biology.

[17]  C. Barbas,et al.  Building zinc fingers by selection: toward a therapeutic application. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Ullrich,et al.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.

[19]  B. Groner,et al.  Overexpression of the c‐erbB‐2 protein in human breast tumor cell lines , 1989, Journal of cellular biochemistry.

[20]  R. Neve,et al.  Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells , 2000, Oncogene.

[21]  J R Desjarlais,et al.  Use of a zinc-finger consensus sequence framework and specificity rules to design specific DNA binding proteins. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. Cech,et al.  The Tetrahymena ribozyme acts like an RNA restriction endonuclease , 1986, Nature.

[23]  R. Weinberg,et al.  Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  C. Pabo,et al.  Zinc finger phage: affinity selection of fingers with new DNA-binding specificities. , 1994, Science.

[25]  Lin Chen,et al.  Combinatorial gene regulation by eukaryotic transcription factors. , 1999, Current opinion in structural biology.

[26]  D J Segal,et al.  Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J R Desjarlais,et al.  Toward rules relating zinc finger protein sequences and DNA binding site preferences. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Kraus,et al.  Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.

[29]  R. Cardiff,et al.  Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.

[30]  M. Kraus,et al.  Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  N. Hynes,et al.  The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.

[32]  F. Maurer,et al.  Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. , 1997, Cancer research.

[33]  W. Schaffner,et al.  Different activation domains stimulate transcription from remote (‘enhancer’) and proximal (‘promoter’) positions. , 1992, The EMBO journal.

[34]  H. Thiesen,et al.  Krüppel-associated boxes are potent transcriptional repression domains. , 1994, Proceedings of the National Academy of Sciences of the United States of America.